| First Author | Park KR | Year | 2019 |
| Journal | PLoS One | Volume | 14 |
| Issue | 5 | Pages | e0217037 |
| PubMed ID | 31112565 | Mgi Jnum | J:275819 |
| Mgi Id | MGI:6306757 | Doi | 10.1371/journal.pone.0217037 |
| Citation | Park KR, et al. (2019) Loss of parkin reduces lung tumor development by blocking p21 degradation. PLoS One 14(5):e0217037 |
| abstractText | Several epidemiological studies have demonstrated the reciprocal relationship between the development of cancer and Parkinson's disease (PD). However, the possible mechanisms underlying this relationship remain unclear. To identify this relationship, we first compared lung tumor growth in parkin knockout (KO) mice and wild-type (WT) mice. Parkin KO mice showed decreased lung tumor growth and increased expression of p21, a cell cycle arrester, as compared with WT mice. We also found that parkin interacts with p21, resulting in its degradation; however, parkin KO, knockdown, as well as mutation (R275W or G430D) reduced the degradation of p21. We investigated whether parkin KO increases the association of p21 with proliferating cell nuclear antigen (PCNA) or CDK2 by reducing p21 degradation, and, thus, arresting the cell cycle. The interaction between p21 and PCNA or CDK2 was also enhanced by parkin knockdown, and this increased interaction induced sub G0/G1 arrest, leading to cell death. Therefore, our data indicate that parkin KO reduces the development of lung tumors via cell cycle arrest by blocking the degradation of p21. These findings suggest that PD could be associated with lower lung cancer incidence. |
